Product/Programme
Preclinical
Phase I
Phase II
Phase III
Key Catalysts
POLB 001
Cancer immunotherapy-induced CRS
Positive data from Phase 1b & in vivo study. Phase 2 enabling activities ongoing. Partnering ready
Oral Encapsulated GLP-1R Agonist
Obesity & diabetes treatment
Proof of technology clinical trial expected to commence in 2024
Influenza AI Programme
Utilising unique licensed human viral challenge data
Outputs received Q2 2023 & prioritised targets endorsed by Poolbeg’s Scientific Advisory Board
RSV AI Programme
Utilising unique licensed human viral challenge data
Drug candidates identified and now prioritised following positive outputs from lab-based analysis
Exclusive Option Agreement
Topical muco-adherent Pentoxifylline (tPTX)
Orphan drug candidate for Behçet’s Disease
Conducting due diligence including engagement with Silk Road Therapeutics to ascertain the clinical approval pathway
- Strategic collaboration with Nasdaq listed company for the development of an optimised oral drug to treat a metabolic condition. Learn more
- €2.3m in non-dilutive grant funding secured by Poolbeg led consortium to develop a Phase I clinical trial ready oral vaccine candidate. Learn more
